ORAPI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.2 EUR | -0.64% |
|
+4.03% | -3.73% |
| Apr. 17 | Orapi SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 12 | Orapi: Groupe Paredes holds almost 90% of the capital | CF |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The stock, which is currently worth 2024 to 0.42 times its sales, is clearly overvalued in comparison with peers.
- The opinion of analysts covering the stock has improved over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Commodity Chemicals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -3.73% | 43.5M | - | ||
| -1.20% | 66.01B | A- | ||
| +47.62% | 41.76B | B | ||
| +15.99% | 38.66B | B | ||
| +4.25% | 32.28B | A- | ||
| +8.78% | 19.57B | B- | ||
| +12.32% | 16.77B | C+ | ||
| +17.69% | 15.08B | B- | ||
| +8.31% | 14.83B | B | ||
| -14.59% | 13.95B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ORAP Stock
- Ratings ORAPI
